In this study, we have explored the ability use of the CRISPR/Cas9 technology to obliterate BCR-ABL fusion in order to determine its impact on the leukemic processes in in vitro and in xenograft models of CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.